Device Trial Radar · NCT05882318
Effectiveness of eCoin at Sensory and Subsensory Amplitudes
Last checked: Nov 20, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 6, 2023
Primary completion
Apr 19, 2024
Study completion May 14, 2024
Sponsor
- Lead sponsor
- Valencia Technologies CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). The main question it aims to answer is: * The reduction in UUI episodes per day on a 3-day voiding diary in both groups after 3 months of therapy Participants will be implanted with the eCoin device and randomized to either a sensory or subsensory stimulation group and complete voiding diaries and patient reported-outcomes through 3 months of therapy. After 3 months, subjects will be unblinded and reprogramming will be offered. Subjects will be followed for an additional month to a total of 4 months.
Conditions
- Urge Incontinence
Interventions
eCoin Peripheral Neurostimulator SystemDevice
The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in UUI Episodes Per DayTime frame: 3 months post-activation
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Genesis Research
Downey, California
Urology Associates of Central California
Fresno, California
The Iowa Clinic
Ankeny, Iowa
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.